Format

Send to

Choose Destination
Front Immunol. 2012 Jul 20;3:212. doi: 10.3389/fimmu.2012.00212. eCollection 2012.

Immunomodulatory effect of mesenchymal stem cells on B cells.

Author information

1
Department of Internal Medicine, Erasmus Medical Center Rotterdam, Netherlands.

Abstract

The research on T cell immunosuppression therapies has attracted most of the attention in clinical transplantation. However, B cells and humoral immune responses are increasingly acknowledged as crucial mediators of chronic allograft rejection. Indeed, humoral immune responses can lead to renal allograft rejection even in patients whose cell-mediated immune responses are well controlled. On the other hand, newly studied B cell subsets with regulatory effects have been linked to tolerance achievement in transplantation. Better understanding of the regulatory and effector B cell responses may therefore lead to new therapeutic approaches. Mesenchymal stem cells (MSC) are arising as a potent therapeutic tool in transplantation due to their regenerative and immunomodulatory properties. The research on MSCs has mainly focused on their effects on T cells and although data regarding the modulatory effects of MSCs on alloantigen-specific humoral response in humans is scarce, it has been demonstrated that MSCs significantly affect B cell functioning. In the present review we will analyze and discuss the results in this field.

KEYWORDS:

B cells; MSC; chronic allograft rejection; humoral rejection; immunomodulation

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center